AccessibilityHelpAbout Us
Arovella Therapeutics Ltd logo

Arovella Therapeutics Ltd(ASX) ALA

Market CapA$72.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-98%
5 Year+11%
1 Year-25%
1 Month+0%
A$0.06
+1.67%
+0.00Today
Arovella Therapeutics Ltd last closing stock price
MetricPriceDate
Last closeAUD 0.062026-09-09
Arovella Therapeutics Ltd stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.062026-09-02
1 month+0%AUD 0.062026-08-10
3 month-9.09%AUD 0.072026-06-11
Year to date-35.48%AUD 0.092025-12-31
1 year-25%AUD 0.082025-09-09
3 year-10.45%AUD 0.072023-09-08
5 year+11.11%AUD 0.052021-09-10
Since inception-97.91%AUD 2.872002-01-24

Arovella Therapeutics Ltd Financials at a Glance

Market Cap

A$72.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$136.00K

Net Income (TTM)

-A$14.43M

EPS (TTM)

-A$0.01

P/E Ratio

-10.34

Dividend

A$0.00

Beta (Volatility)

0.08 (Low)

Price

A$0.06

Volume

98,339

Open

A$0.06

Previous Close

A$0.06

Daily Range

A$0.06 - A$0.06

52-Week Range

A$0.06 - A$0.13

Estimated Earnings Date

Feb 25, 2027

ALA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Arovella Therapeutics Ltd

Arovella Therapeutics Limited is an Australian biotechnology firm focused on developing innovative therapeutic solutions for oncology and central nervous system disorders. The company operates both domestically and internationally, with a diverse pipeline of products aimed at addressing significant medical needs.

Products and Services
  • ZolpiMist: An oral spray formulation for short-term insomnia treatment
  • Invariant natural killer T (iNKT) cell therapy platform targeting blood cancers
  • OroMist technology for drug delivery via the oral cavity
Growth Outlook
  • Strong pipeline with multiple therapeutic candidates in development
  • Research collaboration with Imperial College London enhances innovation
  • Focus on expanding product applications in various medical conditions
Financial Highlights
  • Cash and cash equivalents of AUD 14.35 million as of June 30, 2026
  • Current ratio of 17.51 indicates strong liquidity position
  • Net income of AUD -5.04 million for the latest quarter
Arovella Therapeutics Limited is positioned in the biotechnology sector, with a commitment to addressing unmet medical needs through its innovative product offerings. The company’s focus on research and development, particularly in oncology and central nervous system disorders, reflects its strategic intent to capture significant market opportunities. The collaboration with Imperial College London is expected to bolster its research capabilities, potentially leading to groundbreaking therapies. Financially, Arovella maintains a robust liquidity position, as evidenced by its current ratio, which suggests the ability to meet short-term obligations. However, the company has reported net losses in recent quarters, indicative of the typical financial trajectory for biotechnology firms in the development phase. Investors may find Arovella's growth potential appealing, given its strategic focus and innovative pipeline.
AI Generated • Sep 4, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Nicole Louise van der Weerden, PhD, MBA

Website

www.arovella.com

Headquarters

Preston, VIC 3072, AU

ALA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-41.83%

Return on Capital

-79.24%

Return on Assets

-46.08%

Earnings Yield

-9.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$72.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.21B

Volume

98.34K

Avg. Volume

675.68K

Financials (TTM)

Gross Profit

A$18.29K

Operating Income

-A$22.42M

EBITDA

-A$30.02M

Operating Cash Flow

-A$13.84M

Capital Expenditure

-A$452.16K

Free Cash Flow

-A$14.29M

Cash & ST Invst.

A$14.35M

Total Debt

A$0.00

Arovella Therapeutics Ltd Performance Analysis

Arovella Therapeutics Ltd annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 405,89837.2%
20242024-06-30AUD 17,000-95.8%
20252025-06-30AUD 136,000700.0%
20262026-06-30AUD 0N/A
Arovella Therapeutics Ltd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3040361.9%
Q42025-06-30-196.0%
Q22025-12-31100.0%
Q42026-06-30N/A
Arovella Therapeutics Ltd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-8.9%
20242024-06-30AUD -0.01-35.0%
20252025-06-30AUD -0.01-26.9%
20262026-06-30AUD -0.01-14.7%
Arovella Therapeutics Ltd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3070.8%
Q42025-06-30-285.7%
Q22025-12-3170.4%
Q42026-06-30-162.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$58.56K

-788.9%

Gross Margin

0.00%

N/A

Market Cap

A$72.53MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.69M

N/A

Employees

27

N/A

Net Income

-A$5.04M

-4.9%

EBITDA

-A$5.65M

-17.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$14.35M

+12.9%

Total Debt

A$0.00

N/A

Accounts Receivable

A$0.00

N/A

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-46.08%

N/A

Return on Invested Capital

-79.13%

N/A

Free Cash Flow

-A$5.19M

-18.8%

Operating Cash Flow

-A$5.20M

-21.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATX.AXAmplia Therapeutics Limited
A$0.12-7.69%
BIO.AXBiome Australia Limited
A$0.37+2.78%
ATH.AXAlterity Therapeutics Limited
A$0.48-4.95%
RCE.AXRecce Pharmaceuticals Ltd
A$0.37+4.23%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.55-0.04%
INTCIntel
$106.24+0.02%
NOKNokia
$10.76+0.01%
NVDANvidia
$223.67-0.01%

Questions About ALA

What is the current price of Arovella Therapeutics Ltd?

Arovella Therapeutics Ltd is trading at A$0.06 per share.

What is the 52-week range for Arovella Therapeutics Ltd?

Over the past 52 weeks, Arovella Therapeutics Ltd has traded between A$0.06 and A$0.13.

How much debt does Arovella Therapeutics Ltd have?

As of the most recent reporting period, Arovella Therapeutics Ltd reported total debt of A$0.00.

How much cash does Arovella Therapeutics Ltd have on hand?

Arovella Therapeutics Ltd reported A$14.35M in cash and cash equivalents in its most recent financial results.

What is Arovella Therapeutics Ltd’s dividend yield?

Arovella Therapeutics Ltd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services